このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure (GOAL-HF2)

2026年11月6日 更新者:AnaCardio AB

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of 2 Dose Levels of the Oral Ghrelin Receptor Agonist AC01 Over 12 Weeks in Patients With Chronic Advanced Heart Failure With Reduced Ejection Fraction (HFrEF)

The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.

調査の概要

詳細な説明

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study designed to evaluate the safety and efficacy of the ghrelin-receptor agonist AC01 compared to placebo in participants with chronic advanced HFrEF. Approximately 400 participants will be randomized to 1 of 3 treatment arms: 3 milligram (mg) AC01, 1 milligram (mg) AC01, or placebo twice daily for 12 weeks. The primary objective is to evaluate the effect of AC01 compared to placebo on cardiac structure and function assessed by echocardiography.

研究の種類

介入

入学 (推定)

400

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Van Nuys、California、アメリカ、91405-2272
        • 募集
        • Progressive MD, InvivoCure
    • Florida
      • Crystal River、Florida、アメリカ、34429
        • 募集
        • Nature Coast Clinical Research
    • Illinois
      • Schaumburg、Illinois、アメリカ、60173
        • 募集
        • Chicago Cardiology Institute
    • Pennsylvania
      • Camp Hill、Pennsylvania、アメリカ、17011
        • 募集
        • Capital Area Research, LLC - Camp Hill
      • Trois-Rivières、カナダ、G9A 4P3
        • 募集
        • Diex Recherche Trois-Rivières
    • Québec (QC)
      • Sherbrooke、Québec (QC)、カナダ、J1L 0H8
        • 募集
        • Diex Recherche Sherbrooke
      • Gothenburg、スウェーデン、41345
        • 募集
        • Sahlgrenska Universitetssjukhuset
      • Palma、スペイン、07198
        • 募集
        • Hospital SON LLATZER
      • Prešov、スロバキア、08001
        • 募集
        • MUDr. Daniela Viňanská Interná a kardiologická ambulancia, Medispol, s.r.o
      • Klatovy、チェコ、33901
        • 募集
        • Kardio Michal Čepelák, s.r.o.
      • Blagoevgrad、ブルガリア、2700
        • 募集
        • Multi-Profile Hospital for Active Treatment (MHAT) - Hospital Puls
      • Burgas、ブルガリア、8000
        • 募集
        • Medical Center I - Burgas
      • Pleven、ブルガリア、5800
        • 募集
        • Medical Center Medconsult Pleven
      • Oświęcim、ポーランド、32600
        • 募集
        • Medicome Sp z o.o. Oswiecimskie Centrum Medyczne

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~85年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  • History of Chronic Heart Failure (CHF) diagnosed greater than or equal to (>=6) months before screening, and in NYHA Class II to IV at screening.

  • Chronic advanced HFrEF defined as:

    • LVEF less than or equal to (<=) 35 percentage (%) by local reading >=6 months before screening or a record of LVEF qualitatively described as severely reduced or moderately-severely reduced >=6 months before screening, and
    • LVEF <=35% at the screening echocardiography (confirmed by core lab), and
    • no known LVEF greater than (>) 35% (or qualitatively described as less than moderately-severely reduced) between the 2 readings.
  • Sinus rhythm or permanent, persistent, or paroxysmal atrial fibrillation flutter (AFF) (AFF at screening is capped at maximum 15% of participants enrolled) with mean resting heart rate of >=55 and <=90 beats per minute (bpm) at screening, and >=50 and <=95 bpm at randomization, regardless of rhythm.

  • NT-proBNP >=400 picograms per milliliter (pg/mL) in sinus rhythm and >=800 pg/mL in AFF at screening (confirmed by central laboratory).

  • Transvenous implantable cardioverter-defibrillator (ICD) for primary prevention with back-up pacing set at 40 bpm.

  • Treated with optimal, stable, medical therapy for HF consistent with prevailing local and international guidelines unless contraindicated or not tolerated, as judged and documented by the investigator.

Key Exclusion Criteria:

  • Any acute or serious co-morbid condition that could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.
  • Admitted to hospital with the primary reason of HF within 24 hours before randomization or currently hospitalized with the primary reason of HF for more than 10 days. Current hospitalization (>24 hours and <=10 days) is capped at a maximum of 15% of participants enrolled.
  • Acute coronary syndrome, stroke or transient ischemic attack, severe ventricular arrhythmia, or major cardiac intervention, percutaneous coronary intervention, valvuloplasty/other cardiac valve repair or implantation, or cardiac surgery within 60 days before randomization.
  • Systolic blood pressure >130 or ˂90 millimeters of mercury (mmHg) at screening, or >140 or ˂85 mmHg at randomization.
  • Uncontrolled diabetes mellitus, defined as Hemoglobin A1c (HbA1c) >=9.0% (>=75 millimoles per mole [mmol/mol]) at screening, or severe complications of diabetes.
  • Body weight <50 kilogram (kg) or body mass index (BMI) <18 kilograms per square meter (kg/m^2) or >45 kg/m^2 at screening.
  • Any of the following electrocardiogram (ECG) findings at screening: Corrected QT interval using Fridericia's formula (QTcF) >450 milliseconds (ms), 1st degree atrioventricular (AV) block with PQ >240 ms, or AV block 2nd or 3rd degree.
  • History of aborted cardiac arrest, sustained ventricular tachycardia, or Torsades-de Pointes, or congenital long QT syndrome. Family history of sudden cardiac death, unexplained death, long QT syndrome, or death from a primary dysrhythmia.
  • Cardiac resynchronization therapy, Cardiac Contractility Modulation, or pacemaker device other than the back-up pacing function of the ICD.
  • Mechanical hemodynamic support, kidney support, or ventilation within 7 days before randomization.
  • Treatment with i.v. inotropes, i.v. vasodilators, or i.v. vasopressors within 3 days before randomization.
  • Treatment with any i.v. diuretics or supplemental oxygen within 6 hours before randomization.
  • Use of any drugs or substances known to be strong inducers of Cytochrome P450 3A4 (CYP3A4) enzyme within 28 days before randomization or planned to be used during the study period or strong inhibitors of CYP3A4 within 7 days before randomization or planned to be used during the study period.
  • Use of any drug that is known to prolong the QT interval (for example, sotalol, dofetilide, macrolides, some antidepressants, and some antipsychotics) within 28 days before randomization or planned to be used during the study period.
  • Treatment changes in glucose lowering therapy within 28 days before randomization.
  • Estimated glomerular filtration rate (eGFR) <20 milliliters per minute per 1.73 square meters (mL/min/1.73 m2) according to the Chronic Kidney Disease Epidemiology Collaboration formula, planned renal replacement therapy within the next 6 months, or receiving dialysis at screening.
  • Serum potassium <3.5 or >5.2 milliequivalents per liter (mEq/L) at screening.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 *upper limit of normal (ULN) or total bilirubin >2 * ULN, or known cirrhosis, severe liver, or pancreatic disease at screening.
  • Use of any anti-arrhythmic drugs within 28 days before randomization or planned to be used during the study period, except for amiodarone, ivabradine, digoxin, and beta blockers.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:AC01 3 mg

Participants will receive AC01 orally twice daily (BID) for 12 weeks.

AC01 tablets for oral administration.

実験的:AC01 1 mg

Participants will receive AC01 orally BID for 12 weeks.

AC01 tablets for oral administration.

プラセボコンパレーター:Placebo

Participants will receive matching placebo orally BID for 12 weeks.

AC01 matching placebo tablets for oral administration.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Absolute Change from Baseline in Composite Echocardiography Z-Score at Week 12
時間枠:Baseline and Week 12

The composite echocardiography Z-score integrates left ventricular stroke volume (LVSV), left ventricular end systolic volume (LVESV), left ventricular ejection fraction (LVEF), and left atrial minimal volume index (LAVImin).

Baseline and Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Absolute Change from Baseline in LVSV at Week 12
時間枠:Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in LVEF at Week 12
時間枠:Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in LVESV at Week 12
時間枠:Baseline and Week 12
Baseline and Week 12
Absolute Change From Baseline in LAVImin at Week 12
時間枠:Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in N-terminal prohormone of Brain Natriuretic Peptide (NT-proBNP)
時間枠:Baseline and Week 12
Baseline and Week 12
Number of Participants With Death, Cardiovascular Death, Hospitalization, Cardiovascular Hospitalization, Heart Failure Hospitalization, Heart Failure Events, Other Adjudicated Events, and Listed for Heart Transplantation
時間枠:At Week 12
At Week 12
Change From Baseline in Guideline-directed Medical Therapy (GDMT) Use for HFrEF at Week 12
時間枠:Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
時間枠:Baseline and Week 12
Baseline and Week 12
Number of Participants With Dialysis
時間枠:At Week 12
At Week 12
Absolute Change From Baseline in New York Heart Association (NYHA) Class
時間枠:Baseline and Week 12
Baseline and Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs)
時間枠:From first dose of study drug up to end of follow up (up to Week 16)
From first dose of study drug up to end of follow up (up to Week 16)
Absolute Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) at Week 12
時間枠:Baseline and Week 12

The KCCQ is a validated, 23-item, self-administered questionnaire designed to assess health status in participants with congestive heart failure. It evaluates six domains: symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability. Each domain score is transformed to a scale of 0 to 100, with higher scores indicating better health status. The KCCQ-TSS is derived from the domain scores.

Baseline and Week 12
Absolute Change From Baseline in Patient Global Impression of Severity (PGIS) at Week 12
時間枠:Baseline and Week 12

PGIS is 1-item questionnaire used to rate the severity of a specific condition. Participants record their perceived severity of heart failure (HF) symptoms, specifically shortness of breath, fatigue, and swelling, and choose 1 response that best described the extent of their symptoms based on a 5-point scale. Response options include none, mild, moderate, severe, and very severe. Higher PGIS scores indicate more severe HF symptoms; lower scores indicate less severe symptoms.

Baseline and Week 12
Patient Global Impression of Change (PGIC) at Week 12
時間枠:At Week 12

The PGIC questionnaire is administered to assess the participant's impression of change in HF symptoms since the initiation of study treatment, specifically changes in shortness of breath, fatigue, and swelling. Participants select one response to describe the overall change (if any) in HF symptoms on a 7-category scale: 7=very much improved, 6 =much improved, 5 =minimally improved, 4 =no change, 3 =minimally worse, 2 =much worse, and 1 =very much worse. Higher PGIC scores indicate greater improvement in HF symptoms, while lower scores indicate worsening or no change.

At Week 12
Absolute Change from Baseline in Council on Nutrition Appetite Questionnaire (CNAQ) Total Score
時間枠:Baseline and Week 12

The CNAQ is an 8-item, self-administered questionnaire used to assess appetite over time. Each item is scored on a scale of 1 to 5, and the total score is calculated as the sum of all item scores. The instrument has demonstrated acceptable psychometric properties, including internal consistency, construct validity, and predictive validity, for assessing appetite in participants with heart failure. Higher CNAQ scores indicate better appetite.

Baseline and Week 12
AUC,ss: Area Under the Concentration-Time Curve at Steady State of AC01 and its Metabolite M6
時間枠:At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Cmax,ss: Maximum Observed Concentration at Steady State of AC01 and its Metabolite M6
時間枠:At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Tmax,ss: Time to Reach Maximum Concentration at Steady State
時間枠:At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Ctrough: Trough concentration at steady state of AC01 and its Metabolite M6
時間枠:At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Rac (Cmax): Accumulation Ratio of Cmax for AC01 and its Metabolite M6
時間枠:At Week 4 and Week 12

Population pharmacokinetic parameters. Accumulation ratio of Cmax calculated as Cmax at Week 12/Cmax at Week 4.

At Week 4 and Week 12
Rac (AUC): Accumulation Ratio of AUC for AC01 and its Metabolite M6
時間枠:At Week 4 and Week 12

Population pharmacokinetic parameters. Accumulation ratio of AUC calculated as AUC at Week 12/AUC at Week 4.

At Week 4 and Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月15日

一次修了 (推定)

2028年7月30日

研究の完了 (推定)

2028年8月30日

試験登録日

最初に提出

2026年5月4日

QC基準を満たした最初の提出物

2026年5月8日

最初の投稿 (実際)

2026年5月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • AC01-02
  • 2025-524469-25-00 (Ctis)
  • PIP number (その他の識別子:EMA/PE/0000267875)
  • 2025 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Individual de-identified participant data will be shared with qualified scientific and medical researchers whose proposed use of data has been approved by the study executive committee, beginning 9 months and ending 36 months following article publication. Proposals should be directed to the Central Contact Person.

IPD 共有時間枠

Links to the Study Protocol and Statistical Analysis Plan will be made available on ClinicalTrials.gov

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する